ADAR1 Capital Management LLC Buys New Position in Vaxcyte, Inc. $PCVX

Key Points

• ADAR1 Capital Management LLC has acquired 12,800 shares of Vaxcyte, Inc., valued at approximately $483,000, marking a significant new investment in the company.
• Vaxcyte has a consensus rating of "Buy" from analysts, with a price target of $136.50, indicating potential growth in stock value.
• The company's stock has seen volatility, with a 52-week range between $27.66 and $121.06 and an earnings report indicating a loss of $1.22 per share, missing estimates.

ADAR1 Capital Management LLC purchased a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the first quarter, according to its most recent filing with the SEC. The fund purchased 12,800 shares of the company's stock, valued at approximately $483,000.

A number of other institutional investors have also recently added to or reduced their stakes in PCVX. AlphaQuest LLC bought a new position in Vaxcyte during the 1st quarter worth $33,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Vaxcyte during the 1st quarter worth $35,000. Parallel Advisors LLC grew its stake in Vaxcyte by 203.6% during the 1st quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock worth $61,000 after buying an additional 1,071 shares during the last quarter. IFP Advisors Inc grew its stake in Vaxcyte by 376.4% during the 1st quarter. IFP Advisors Inc now owns 1,653 shares of the company's stock worth $62,000 after buying an additional 1,306 shares during the last quarter. Finally, Twin Tree Management LP grew its stake in Vaxcyte by 301.3% during the 1st quarter. Twin Tree Management LP now owns 2,365 shares of the company's stock worth $89,000 after buying an additional 3,540 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Cowen restated a "buy" rating on shares of Vaxcyte in a research note on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $130.00.

Vaxcyte Stock Up 2.7%

PCVX stock traded up $0.87 during trading on Friday, reaching $33.02. 1,375,472 shares of the company's stock were exchanged, compared to its average volume of 1,478,937. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $121.06. The company's fifty day moving average price is $33.22 and its 200-day moving average price is $40.97. The firm has a market cap of $4.29 billion, a PE ratio of -8.03 and a beta of 1.04.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same period in the prior year, the business posted ($1.10) earnings per share. As a group, sell-side analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.